{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:47:33Z","timestamp":1794624453329,"version":"4.9.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Health (NIH) and National Institute on Aging","award":["P30 AG059301"],"award-info":[{"award-number":["P30 AG059301"]}]},{"name":"National Cancer Institute","award":["P30CA142543"],"award-info":[{"award-number":["P30CA142543"]}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"crossref","award":["RP210130"],"award-info":[{"award-number":["RP210130"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>While the association between metformin and mortality in obesity-related cancers (ORC: breast (BrCa), colorectal (CRC), endometrial (ECa), and ovarian (OCa)) remains inconsistent, the impact of weight loss medication (WLM) on mortality in ORC is largely unexplored, particularly among older women. This study aims to investigate the association between pre-diagnostic use of metformin and WLM with all-cause and cancer-specific mortality in older women with ORC. A retrospective cohort of 63,907 women (\u2265\u200965 years) with ORC was identified using SEER-Medicare 2007\u20132015 data. Pre-diagnostic prescriptions of metformin and WLM were ascertained, and inverse probability of treatment weighting using propensity score (IPTW-PS) was utilized to balance baseline patient characteristics. Cox proportional hazards and competing-risks models were conducted. Metformin was associated with all-cause- (HR:1.86; 95% CI: 1.81\u20131.92) and ORC-specific mortality (HR: 1.71; 95% CI: 1.63\u20131.77). Likewise, WLM was associated with all-cause- (HR:1.64; 95% CI: 1.59\u20131.71) and ORC-specific mortality (HR: 1.55; 95% CI: 1.48\u20131.62). Dual use of metformin and WLM was associated with all-cause- (HR:1.39; 95% CI: 1.34\u20131.45) and ORC-specific mortality (HR: 1.28; 95% CI: 1.21\u20131.53). Significant associations were observed in ORC subgroup analyses, except that WLM was inversely associated with ECa-specific morality. Pre-diagnostic metformin and WLM were associated with an increased mortality risk in older women with ORC, with effects more pronounced among metformin users. Further prospective studies are needed to substantiate these findings.<\/jats:p>","DOI":"10.1038\/s41598-025-09393-1","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T18:47:55Z","timestamp":1751395675000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metformin and weight loss medication impact on survival outcomes in older women with obesity-related cancers"],"prefix":"10.1038","volume":"15","author":[{"given":"Maryam R.","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Abdelgadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Fang","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Canfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"9393_CR1","first-page":"1","volume":"360","author":"CM Hales","year":"2020","unstructured":"Hales, C. M., Carroll, M. D., Fryar, C. D. & Ogden, C. L. Prevalence of obesity and severe obesity among adults: united states, 2017\u20132018. NCHS Data Brief. 360, 1\u20138 (2020).","journal-title":"NCHS Data Brief."},{"key":"9393_CR2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc1408","volume":"4","author":"EE Calle","year":"2004","unstructured":"Calle, E. E. & Kaaks, R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer. 4, 579\u2013591 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"9393_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/2327-6924.12510","volume":"29","author":"SM Fruh","year":"2017","unstructured":"Fruh, S. M. Obesity: risk factors, complications, and strategies for sustainable long-term weight management. J. Am. Assoc. Nurse Pract. 29, S3\u2013S14 (2017).","journal-title":"J. Am. Assoc. Nurse Pract."},{"key":"9393_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/cancers15020485","volume":"15","author":"S Pati","year":"2023","unstructured":"Pati, S. et al. Obesity and cancer: A current overview of epidemiology, pathogenesis, outcomes, and management. Cancers (Basel). 15, 485 (2023).","journal-title":"Cancers (Basel)"},{"key":"9393_CR5","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrc3967","volume":"15","author":"AG Renehan","year":"2015","unstructured":"Renehan, A. G., Zwahlen, M. & Egger, M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat. Rev. Cancer. 15, 484\u2013498 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"9393_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/epirev\/mxt010","volume":"36","author":"MF Munsell","year":"2014","unstructured":"Munsell, M. F. et al. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol. Rev. 36, 114\u2013136 (2014).","journal-title":"Epidemiol. Rev."},{"key":"9393_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L. et al. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"9393_CR8","doi-asserted-by":"crossref","unstructured":"Jensen, M. D. et al. AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129, S102\u2013S138 (2014). (2013).","DOI":"10.1161\/01.cir.0000437739.71477.ee"},{"key":"9393_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s13679-015-0161-z","volume":"4","author":"LE Gill","year":"2015","unstructured":"Gill, L. E., Bartels, S. J. & Batsis, J. A. Weight management in older adults. Curr. Obes. Rep. 4, 379\u2013388 (2015).","journal-title":"Curr. Obes. Rep."},{"key":"9393_CR10","doi-asserted-by":"publisher","first-page":"204209862093374","DOI":"10.1177\/2042098620933741","volume":"11","author":"M Khezrian","year":"2020","unstructured":"Khezrian, M., McNeil, C. J., Murray, A. D. & Myint, P. K. An overview of prevalence, determinants and health outcomes of polypharmacy. Ther. Adv. Drug Saf. 11, 2042098620933741 (2020).","journal-title":"Ther. Adv. Drug Saf."},{"key":"9393_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s13679-019-00335-3","volume":"8","author":"A Yerevanian","year":"2019","unstructured":"Yerevanian, A. & Soukas, A. A. Metformin: mechanisms in human obesity and weight loss. Curr. Obes. Rep. 8, 156\u2013164 (2019).","journal-title":"Curr. Obes. Rep."},{"key":"9393_CR12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.phrs.2016.10.006","volume":"113","author":"M Daugan","year":"2016","unstructured":"Daugan, M. et al. Metformin: an anti-diabetic drug to fight cancer. Pharmacol. Res. 113, 675\u2013685 (2016).","journal-title":"Pharmacol. Res."},{"key":"9393_CR13","doi-asserted-by":"publisher","first-page":"pkx007","DOI":"10.1093\/jncics\/pkx007","volume":"1","author":"X Cao","year":"2017","unstructured":"Cao, X. et al. The effect of Metformin on mortality among diabetic cancer patients: A systematic review and meta-analysis. JNCI Cancer Spectr. 1, pkx007 (2017).","journal-title":"JNCI Cancer Spectr."},{"key":"9393_CR14","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1158\/1055-9965.EPI-14-0327","volume":"23","author":"IC Lega","year":"2014","unstructured":"Lega, I. C. et al. The effect of Metformin on mortality following cancer among patients with diabetes. Cancer Epidemiol. Biomarkers Prev. 23, 1974\u20131984 (2014).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"9393_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.canep.2012.12.009","volume":"37","author":"P Zhang","year":"2013","unstructured":"Zhang, P. et al. Association of Metformin use with cancer incidence and mortality: A meta-analysis. Cancer Epidemiol. 37, 207\u2013218 (2013).","journal-title":"Cancer Epidemiol."},{"key":"9393_CR16","doi-asserted-by":"publisher","first-page":"e33411","DOI":"10.1371\/journal.pone.0033411","volume":"7","author":"H Noto","year":"2012","unstructured":"Noto, H., Goto, A., Tsujimoto, T. & Noda, M. Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis. PLoS One. 7, e33411 (2012).","journal-title":"PLoS One"},{"key":"9393_CR17","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1002\/ijc.29944","volume":"138","author":"Z Gong","year":"2016","unstructured":"Gong, Z. et al. Diabetes, Metformin and incidence of and death from invasive cancer in postmenopausal women: results from the women\u2019s health initiative. Int. J. Cancer. 138, 1915\u20131927 (2016).","journal-title":"Int. J. Cancer"},{"key":"9393_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/1471-2407-12-410","volume":"12","author":"PJ Mazzone","year":"2012","unstructured":"Mazzone, P. J. et al. The effect of Metformin and Thiazolidinedione use on lung cancer in diabetics. BMC Cancer. 12, 410 (2012).","journal-title":"BMC Cancer"},{"key":"9393_CR19","doi-asserted-by":"publisher","first-page":"pkad017","DOI":"10.1093\/jncics\/pkad017","volume":"7","author":"SG Orchard","year":"2023","unstructured":"Orchard, S. G. et al. Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes. JNCI Cancer Spectr. 7, pkad017 (2023).","journal-title":"JNCI Cancer Spectr."},{"key":"9393_CR20","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1001\/jama.2022.6147","volume":"327","author":"PJ Goodwin","year":"2022","unstructured":"Goodwin, P. J. et al. Effect of Metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial. JAMA 327, 1963\u20131973 (2022).","journal-title":"JAMA"},{"key":"9393_CR21","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/jnci\/djae132","volume":"116","author":"C Khouri","year":"2024","unstructured":"Khouri, C. & Suissa, S. R. E. Association of Metformin use and cancer incidence: a systematic review and meta-analysis. J. Natl. Cancer Inst. 116, 1399\u20131400 (2024).","journal-title":"J. Natl. Cancer Inst."},{"key":"9393_CR22","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1001\/jama.2016.7602","volume":"315","author":"R Khera","year":"2016","unstructured":"Khera, R. et al. Association of Pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. JAMA 315, 2424\u20132434 (2016).","journal-title":"JAMA"},{"key":"9393_CR23","unstructured":"The US Food and Drug Administration. 2-13-2020 FDA drug safety communication Silver Spring, MD: The US Food and Drug Administration. (2020). Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/safety-clinical-trial-shows-possible-increased-risk-cancer-weight-loss-medicine-belviq-belviq-xr. Accessed 5 August 2024."},{"key":"9393_CR24","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.2147\/DMSO.S305496","volume":"14","author":"D Funch","year":"2021","unstructured":"Funch, D. et al. Risk of thyroid cancer associated with use of liraglutide and other antidiabetic drugs in a US commercially insured population. Diabetes Metab. Syndr. Obes. 14, 2619\u20132629 (2021).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"9393_CR25","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1210\/en.2009-1272","volume":"151","author":"L Bjerre Knudsen","year":"2010","unstructured":"Bjerre Knudsen, L. et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151, 1473\u20131486 (2010).","journal-title":"Endocrinology"},{"key":"9393_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2012.09.008","volume":"98","author":"C Alves","year":"2012","unstructured":"Alves, C., Batel-Marques, F. & Macedo, A. F. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res. Clin. Pract. 98, 271\u2013284 (2012).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"9393_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s11523-016-0442-9","volume":"11","author":"WZ Wysham","year":"2016","unstructured":"Wysham, W. Z. et al. Effects of fatty acid synthase Inhibition by Orlistat on proliferation of endometrial cancer cell lines. Target. Oncol. 11, 763\u2013769 (2016).","journal-title":"Target. Oncol."},{"key":"9393_CR28","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00404-018-4841-2","volume":"298","author":"H Peng","year":"2018","unstructured":"Peng, H. et al. Orlistat induces apoptosis and protective autophagy in ovarian cancer cells: involvement of Akt-mTOR-mediated signaling pathway. Arch. Gynecol. Obstet. 298, 597\u2013605 (2018).","journal-title":"Arch. Gynecol. Obstet."},{"key":"9393_CR29","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.3390\/cells10082060","volume":"10","author":"BR Jin","year":"2021","unstructured":"Jin, B. R. et al. Anti-obesity drug Orlistat alleviates Western-diet-driven colitis-associated colon cancer via Inhibition of STAT3 and NF-\u03baB-mediated signaling. Cells 10, 2060 (2021).","journal-title":"Cells"},{"key":"9393_CR30","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1186\/s12967-023-04263-8","volume":"21","author":"Y Hua","year":"2023","unstructured":"Hua, Y. et al. Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing. J. Transl Med. 21, 403 (2023).","journal-title":"J. Transl Med."},{"key":"9393_CR31","doi-asserted-by":"crossref","unstructured":"Martinez-Tapia, C. et al. The obesity paradox for mid- and long-term mortality in older cancer patients: A prospective multicenter cohort study. Am. J. Clin. Nutr. 113, 129\u2013141 (2021).","DOI":"10.1093\/ajcn\/nqaa238"},{"key":"9393_CR32","doi-asserted-by":"publisher","first-page":"581799","DOI":"10.3389\/fimmu.2021.581799","volume":"12","author":"J Hartwig","year":"2021","unstructured":"Hartwig, J. et al. Metformin attenuates ROS via FOXO3 activation in immune cells. Front. Immunol. 12, 581799 (2021).","journal-title":"Front. Immunol."},{"issue":"3","key":"9393_CR33","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.tips.2020.01.003","volume":"41","author":"F Marcucci","year":"2020","unstructured":"Marcucci, F., Romeo, E., Caserta, C. A., Rumio, C. & Lefoulon, F. Context-dependent Pharmacological effects of Metformin on the immune system. Trends Pharmacol. Sci. 41 (3), 162\u2013171 (2020).","journal-title":"Trends Pharmacol. Sci."},{"key":"9393_CR34","doi-asserted-by":"crossref","unstructured":"Kwon, Y. J., Kwon, G. E., Lee, H. S., Choi, M. H. & Lee, J. W. The effect of Orlistat on sterol metabolism in obese patients. Front Endocrinol. (Lausanne) 13, 824269 (2022).","DOI":"10.3389\/fendo.2022.824269"},{"issue":"4","key":"9393_CR35","first-page":"785","volume":"67","author":"NF Boyd","year":"1981","unstructured":"Boyd, N. F. et al. Body weight and prognosis in breast cancer. J. Natl. Cancer Inst. 67 (4), 785\u2013789 (1981).","journal-title":"J. Natl. Cancer Inst."},{"issue":"9","key":"9393_CR36","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1097\/IGC.0b013e31822d2aa3","volume":"21","author":"FJ Backes","year":"2011","unstructured":"Backes, F. J. et al. The impact of body weight on ovarian cancer outcomes. Int. J. Gynecol. Cancer. 21 (9), 1601\u20131605 (2011).","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"9393_CR37","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ygyno.2015.10.020","volume":"140","author":"AA Secord","year":"2016","unstructured":"Secord, A. A. et al. Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis. Gynecol. Oncol. 140 (1), 184\u2013190 (2016).","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"9393_CR38","doi-asserted-by":"publisher","first-page":"102241","DOI":"10.1016\/j.esmoop.2024.102241","volume":"9","author":"H Wen","year":"2024","unstructured":"Wen, H. et al. Body mass index, weight change, and cancer prognosis: A meta-analysis and systematic review of 73 cohort studies. ESMO Open. 9 (3), 102241 (2024).","journal-title":"ESMO Open."},{"issue":"9","key":"9393_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11912-016-0539-4","volume":"18","author":"H Lennon","year":"2016","unstructured":"Lennon, H., Sperrin, M., Badrick, E. & Renehan, A. G. The obesity paradox in cancer: A review. Curr. Oncol. Rep. 18 (9), 56 (2016).","journal-title":"Curr. Oncol. Rep."},{"issue":"9","key":"9393_CR40","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/jamaoncol.2016.0732","volume":"2","author":"CH Kroenk","year":"2016","unstructured":"Kroenk, C. H. et al. Analysis of body mass index and mortality in patients with colorectal cancer using causal diagrams. JAMA Oncol. 2 (9), 1137\u20131145 (2016).","journal-title":"JAMA Oncol."},{"key":"9393_CR41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejca.2022.05.020","volume":"172","author":"C Simillis","year":"2022","unstructured":"Simillis, C. et al. A systematic review and meta-analysis assessing the impact of body mass index on long-term survival outcomes after surgery for colorectal cancer. Eur. J. Cancer. 172, 237\u2013251 (2022).","journal-title":"Eur. J. Cancer"},{"issue":"14","key":"9393_CR42","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.3390\/cancers13143592","volume":"13","author":"CC Chiu","year":"2021","unstructured":"Chiu, C. C. et al. Correlation of body mass index with oncologic outcomes in colorectal cancer patients: A large population-based study. Cancers (Basel). 13 (14), 3592 (2021). Published 2021 Jul 17.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"9393_CR43","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/cam4.634","volume":"5","author":"NM Tsang","year":"2016","unstructured":"Tsang, N. M. et al. Overweight and obesity predict better overall survival rates in cancer patients with distant metastases. Cancer Med. 5 (4), 665\u2013675 (2016).","journal-title":"Cancer Med."},{"key":"9393_CR44","doi-asserted-by":"crossref","unstructured":"Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B. & Riley, G. F. Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care. ;40(8):IV-3-18. Suppl. (2002).","DOI":"10.1097\/00005650-200208001-00002"},{"key":"9393_CR45","doi-asserted-by":"crossref","unstructured":"SEER Program. About the SEER Program. Surveillance, Epidemiology, and End Results (SEER) Program. (2023). Available from: https:\/\/seer.cancer.gov\/about\/overview.html. Accessed 5 August 2024.","DOI":"10.1093\/jncimonographs\/lgae033"},{"issue":"2","key":"9393_CR46","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/aje\/155.2.176","volume":"155","author":"MA Hern\u00e1n","year":"2002","unstructured":"Hern\u00e1n, M. A., Hern\u00e1ndez-D\u00edaz, S., Werler, M. M. & Mitchell, A. A. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am. J. Epidemiol. 155 (2), 176\u2013184 (2002).","journal-title":"Am. J. Epidemiol."},{"issue":"3","key":"9393_CR47","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin, P. C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar. Behav. Res. 46 (3), 399\u2013424 (2011).","journal-title":"Multivar. Behav. Res."},{"issue":"11","key":"9393_CR48","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1634\/theoncologist.2015-0096","volume":"20","author":"H Xu","year":"2015","unstructured":"Xu, H. et al. Metformin use is associated with better survival of breast cancer patients with diabetes: A meta-analysis. Oncologist 20 (11), 1236\u20131244 (2015).","journal-title":"Oncologist"},{"issue":"1","key":"9393_CR49","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13058-015-0574-3","volume":"17","author":"HJ Kim","year":"2015","unstructured":"Kim, H. J. et al. Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes. Breast Cancer Res. 17 (1), 64 (2015). Published 2015 May 3.","journal-title":"Breast Cancer Res."},{"issue":"10","key":"9393_CR50","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.2337\/dc12-2535","volume":"36","author":"IC Lega","year":"2013","unstructured":"Lega, I. C. et al. Association between Metformin therapy and mortality after breast cancer: A population-based study. Diabetes Care. 36 (10), 3018\u20133026 (2013).","journal-title":"Diabetes Care"},{"issue":"5","key":"9393_CR51","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.3390\/ijms23052705","volume":"23","author":"M Cejuela","year":"2022","unstructured":"Cejuela, M., Martin-Castillo, B., Menendez, J. A. & Pernas, S. Metformin and breast cancer: where are we now? Int. J. Mol. Sci. 23 (5), 2705 (2022). Published 2022 Feb 28.","journal-title":"Int. J. Mol. Sci."},{"issue":"86","key":"9393_CR52","doi-asserted-by":"publisher","first-page":"35687","DOI":"10.18632\/oncotarget.26286","volume":"9","author":"B Martin-Castillo","year":"2018","unstructured":"Martin-Castillo, B. et al. A phase 2 trial of neoadjuvant Metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. Oncotarget 9 (86), 35687\u201335704 (2018). Published 2018 Nov 2.","journal-title":"Oncotarget"},{"issue":"13","key":"9393_CR53","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1200\/JCO.2016.69.7722","volume":"35","author":"A Sonnenblick","year":"2017","unstructured":"Sonnenblick, A. et al. Impact of diabetes, insulin, and Metformin use on the outcome of patients with human epidermal growth factor receptor 2-positive primary breast cancer: analysis from the ALTTO phase III randomized trial. J. Clin. Oncol. 35 (13), 1421\u20131429 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"9393_CR54","doi-asserted-by":"publisher","first-page":"djv006","DOI":"10.1093\/jnci\/djv006","volume":"107","author":"PJ Goodwin","year":"2015","unstructured":"Goodwin, P. J. et al. Effect of Metformin vs placebo on metabolic factors in NCIC CTG MA.32. J. Natl. Cancer Inst. 107 (3), djv006 (2015). Published 2015 Mar 4.","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"9393_CR55","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2174\/15680266113136660069","volume":"8","author":"PJ Peeters","year":"2013","unstructured":"Peeters, P. J. et al. Use of Metformin and survival of diabetic women with breast cancer. Curr. Drug Saf. 8 (5), 357\u2013363 (2013).","journal-title":"Curr. Drug Saf."},{"key":"9393_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ygyno.2024.01.007","volume":"182","author":"H Xie","year":"2024","unstructured":"Xie, H., Li, M. & Zheng, Y. Associations of Metformin therapy treatment with endometrial cancer risk and prognosis: A systematic review and meta-analysis. Gynecol. Oncol. 182, 15\u201323 (2024).","journal-title":"Gynecol. Oncol."},{"key":"9393_CR57","doi-asserted-by":"publisher","first-page":"101026","DOI":"10.1016\/j.neo.2024.101026","volume":"56","author":"P Kaur","year":"2024","unstructured":"Kaur, P. et al. Metformin use and survival in people with ovarian cancer: A population-based cohort study from British columbia, Canada. Neoplasia 56, 101026 (2024).","journal-title":"Neoplasia"},{"issue":"9","key":"9393_CR58","first-page":"e45421","volume":"15","author":"HS Vemulapalli","year":"2023","unstructured":"Vemulapalli, H. S. et al. Safety and efficacy of liraglutide on cardiovascular outcomes in patients with diabetes mellitus: A meta-analysis of randomized controlled trials. Cureus 15 (9), e45421 (2023). Published 2023 Sep 17.","journal-title":"Cureus"},{"issue":"2","key":"9393_CR59","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ehjcvp\/pvaa133","volume":"8","author":"M Ardissino","year":"2022","unstructured":"Ardissino, M. et al. Long-term cardiovascular outcomes after Orlistat therapy in patients with obesity: A nationwide, propensity-score matched cohort study. Eur. Heart J. Cardiovasc. Pharmacother. 8 (2), 179\u2013186 (2022).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother"},{"issue":"4","key":"9393_CR60","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/oby.22430","volume":"27","author":"KH Lewis","year":"2019","unstructured":"Lewis, K. H. et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obes. (Silver Spring). 27 (4), 591\u2013602 (2019).","journal-title":"Obes. (Silver Spring)"},{"issue":"5","key":"9393_CR61","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3349\/ymj.2006.47.5.614","volume":"47","author":"KK Kim","year":"2006","unstructured":"Kim, K. K., Cho, H. J., Kang, H. C., Youn, B. B. & Lee, K. R. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med. J. 47 (5), 614\u2013625 (2006).","journal-title":"Yonsei Med. J."},{"issue":"1","key":"9393_CR62","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2012.113905","volume":"309","author":"KM Flegal","year":"2013","unstructured":"Flegal, K. M., Kit, B. K., Orpana, H. & Graubard, B. I. Association of all-cause mortality with overweight and obesity using standard body mass index categories: A systematic review and meta-analysis. JAMA 309 (1), 71\u201382 (2013).","journal-title":"JAMA"},{"issue":"3","key":"9393_CR63","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1210\/jc.2016-2573","volume":"102","author":"DM Styne","year":"2017","unstructured":"Styne, D. M. et al. Pediatric obesity-assessment, treatment, and prevention: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 102 (3), 709\u2013757 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"9393_CR64","doi-asserted-by":"publisher","first-page":"373","DOI":"10.7326\/0003-4819-157-5-201209040-00475","volume":"157","author":"VA Moyer","year":"2012","unstructured":"Moyer, V. A. & U.S. Preventive Services Task Force. Screening for and management of obesity in adults: U.S. Preventive services task force recommendation statement. Ann. Intern. Med. 157 (5), 373\u2013378 (2012).","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"9393_CR65","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1002\/oby.22581","volume":"27","author":"DR Saxon","year":"2019","unstructured":"Saxon, D. R. et al. Antiobesity medication use in 2.2 million adults across eight large health care organizations: 2009\u20132015. Obes. (Silver Spring). 27 (12), 1975\u20131981 (2019).","journal-title":"Obes. (Silver Spring)"},{"issue":"8","key":"9393_CR66","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/oby.21136","volume":"23","author":"Y Xia","year":"2015","unstructured":"Xia, Y., Kelton, C. M., Guo, J. J., Bian, B. & Heaton, P. C. Treatment of obesity: pharmacotherapy trends in the united States from 1999 to 2010. Obes. (Silver Spring). 23 (8), 1721\u20131728 (2015).","journal-title":"Obes. (Silver Spring)"},{"issue":"9","key":"9393_CR67","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1002\/oby.21533","volume":"24","author":"CE Thomas","year":"2016","unstructured":"Thomas, C. E., Mauer, E. A., Shukla, A. P., Rathi, S. & Aronne, L. J. Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. Obes. (Silver Spring). 24 (9), 1955\u20131961 (2016).","journal-title":"Obes. (Silver Spring)"},{"issue":"1","key":"9393_CR68","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/oby.2009.175","volume":"18","author":"SD Bolen","year":"2010","unstructured":"Bolen, S. D. et al. Trends in and patterns of obesity reduction medication use in an insured cohort. Obes. (Silver Spring). 18 (1), 206\u2013209 (2010).","journal-title":"Obes. (Silver Spring)"},{"key":"9393_CR69","unstructured":"SEER-Medicare Linked Data Resource. Analytic support for researchers. Measures that are limited or not available in the data. Available from: https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/measures.html. Accessed 23 August 2024."},{"issue":"11","key":"9393_CR70","doi-asserted-by":"publisher","first-page":"8255","DOI":"10.1007\/s00432-023-04778-z","volume":"149","author":"DS Lopez","year":"2023","unstructured":"Lopez, D. S. et al. Use of weight loss medications in relation with prostate, colorectal, and male breast cancers among older men: SEER-Medicare 2007\u20132015. J. Cancer Res. Clin. Oncol. 149 (11), 8255\u20138265 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"9393_CR71","unstructured":"SEER Treatment Data Limitations (November. 2023 Submission) - SEER Data & Software. Available from: https:\/\/seer.cancer.gov\/data-software\/documentation\/seerstat\/nov2023\/treatment-limitations-nov2023.html. Accessed 23 August 2024."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09393-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09393-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09393-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T20:03:07Z","timestamp":1751400187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09393-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9393"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-09393-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u201cThe authors have no relevant financial or non-financial interests to disclose.\u201d. \u201cThis study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the National Cancer Institute; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database.\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and received approval from the Institutional Review Board (IRB) at the University of Texas Medical Branch (UTMB) in Galveston, Texas, USA (IRB Approval Code: 20\u20130237; Approval Date: September 15, 2020). Given the retrospective nature of this de-identified secondary data analysis, the IRB at UTMB approved the waiver of informed consent in accordance with the 45 CFR 46.104.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"21828"}}